Introduction
- Although migraine market revenues have demonstrated almost 12% growth over
the last four years across the seven major pharmaceutical markets reaching
approximately $2.4 billion in 2003, as the market becomes increasingly
crowded, growth is predicted to slow.
Scope of this report
- Overview of current market including profiles of key brands and key events
impacting each brand during 2003-2004
- Assessment of current and future opportunities and threats in the migraine
market across the seven major pharmaceutical markets
- Global sales for leading migraine products are presented, with projections
for future performance up to 2014
- In-depth discussion of assumptions and events used in forecast analysis
Research and analysis highlights
- First-line therapy predominantly utilizes simple analgesics and NSAIDs,
despite the lack of sustained anti-migraine effect seen with these products
and the risk of rebound headaches. Commercial growth of the triptan class
has the potential to be accelerated by encouraging wider and earlier use
through patient and PCP education.
- Preventative treatment will provide further market expansion, however, the
current drugs that are likely to maximize this opportunity are the
anticonvulsants, whereas the prophylaxis market for triptans is likely to be
limited to MAM for the forecast period.
- As patent expiries take effect on the market, it is likely that the focus
on the cost of therapies will increase. Consistent physician valued
differentiation between the oral triptans is currently poor, which, if left
unchecked, will lead to significant cross-brand erosion following the launch
of generic sumatriptan.
Key reasons to read this report
- Quantify future size and scope of the migraine market and potential for
new products
- Understand key drivers to this market and predict future performance of
these compounds
- Identify hot areas of the market not targeted by competitors
View Cart
